{"groups":[{"description":"Participants received pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 2 years. Eligible participants who stopped the initial course of pembrolizumab due to complete response (CR) or completed initial course of pembrolizumab and had stable disease but progressed after discontinuation, initiated a second course of pembrolizumab at the investigator's discretion for up to an additional year.","id":"FG000","title":"Pembrolizumab 200 mg"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"19"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"273"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"13"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"39"}],"type":"Participation in study terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Protocol Violation"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Screen failure"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"374"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"370"}],"type":"Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"13"}],"type":"Received Second Course Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"374"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"Results are based on a database cutoff date of 18-February-2022.","recruitmentDetails":"Participants were eligible to receive second course treatment with pembrolizumab if they met criteria for re-treatment. Per protocol, only data generated during the initial course of treatment contributed to efficacy and safety outcome measures."}